Free tool
FAERS Monitor: Krystexxa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125293 or its brand name (Krystexxa, Pegloticase). Reports on generic versions are filed under their own applications.
Reports
3,875
Serious
1,895
49% of reports
Hospitalization
835
Death reported
135
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- gout575
- blood uric acid increased417
- infusion related reaction367
- therapeutic response decreased240
- dyspnoea184
- drug ineffective155
- nausea150
- urticaria150
- off label use138
- pruritus138
- rash133
- dizziness117
- chest pain116
- pain114
- fatigue107
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 52 |
| 2012 | 78 |
| 2013 | 98 |
| 2014 | 57 |
| 2015 | 48 |
| 2016 | 96 |
| 2017 | 104 |
| 2018 | 264 |
| 2019 | 384 |
| 2020 | 240 |
| 2021 | 101 |
| 2022 | 351 |
| 2023 | 426 |
| 2024 | 582 |
| 2025 | 473 |
| 2026 | 521 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,284 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| blood uric acid increasedSignal | 417 | 422.5 | 384.4 | 162,339 |
| goutSignal | 575 | 179.6 | 166.3 | 98,783 |
| infusion related reactionSignal | 367 | 30.2 | 27.4 | 10,313 |
| therapeutic response decreasedSignal | 240 | 21.6 | 19.1 | 4,682 |
| urticariaSignal | 150 | 4.9 | 4.2 | 460 |
| chest painSignal | 116 | 3.4 | 2.8 | 196 |
| pruritus | 138 | 1.9 | 1.7 | 64 |
| dyspnoea | 184 | 1.8 | 1.5 | 62 |
| rash | 133 | 1.7 | 1.4 | 35 |
| dizziness | 117 | 1.3 | 1.1 | 7 |
| nausea | 150 | 1.0 | 0.9 | 0 |
| pain | 114 | 1.0 | 0.8 | 0 |
| off label use | 138 | 0.9 | 0.7 | 3 |
| fatigue | 107 | 0.7 | 0.6 | 9 |
| drug ineffective | 155 | 0.6 | 0.5 | 33 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.